Why Choose Tataa?
20+ years of leading edge bioanalysis on a global scale
We lead the nucleic acid analysis market with proprietary techniques engineered to support your research needs more efficiently and precisely.
applications
Support at every phase for well-informed decisions
Our molecular analyses support every phase of drug development, from early discovery through biomarker validation to large clinical cohort studies for efficacy and safety. We ensure precise, actionable insights at each stage, enabling informed decisions throughout the development.
Biomarker discovery and validation
Our biomarker discovery and validation services are designed to help you identify and validate biomarkers that predict drug response, efficacy, and safety. We offer comprehensive analysis support, from initial discovery using NGS and qPCR to multiplex protein biomarker validation.
Immunoprofiling and immune response monitoring
We provide advanced immunoprofiling and immune response monitoring services to support the development of immunotherapies, cell and gene therapies, vaccines, and other biologics. Utilizing TCR/BCR sequencing, qPCR/dPCR, NGS, and Olink proteomics, we offer in-depth insights into the immune system’s response.
Cell and gene bioanalysis
We develop and validate highly sensitive assays from complex samples and unique test items through to final data for biodistribution, shedding, PK/PD, and transgene expression. Depending on regulatory requirements, the analysis is performed as fit-for-purpose, GLP, or GCLP.
Small non-coding RNAs
We use Two-tailed PCR technology to analyze short targets such as miRNA and siRNA. This technology enables high-throughput, validated qPCR/dPCR analyses for bioanalysis or biomarker purposes of these short targets.
Gene expression analysis
We offer comprehensive gene expression analysis services from early discovery through preclinical and clinical trials. We develop and validate assays for qPCR, dPCR, and Next-Generation Sequencing (NGS) to deliver precise, reliable, and regulatory-compliant gene expression data.
Genomic profiling and mutation detection
Our genomic profiling and mutation detection services identify key mutations for personalized therapies. We perform whole genome sequencing (WGS), exome sequencing, and targeted gene panels to deliver insights into SNPs, indels, CNVs, and structural variants.
Discovery
Our services in the discovery phase focus on drug target identification and biomarker discovery. We utilize gene expression profiling and genomic analysis to uncover potential drug targets and identify novel biomarkers associated with disease mechanisms. Leveraging advanced technologies such as NGS, qPCR/dPCR, and proteomics, we discover genetic mutations, gene expression patterns, and early-stage biomarkers that can be validated in later phases of development.
Preclinical
In the preclinical phase, our molecular analysis services validate discovered biomarkers and further characterize genomic mutations identified during the discovery phase. We use qPCR, dPCR, and NGS to confirm biomarkers’ accuracy, reproducibility, and clinical relevance. Additionally, our genomic profiling ensures the integrity of cell and gene therapies, identifying potential mutations or safety risks in therapeutic models before progressing to clinical trials.
Clinical
We leverage qPCR, dPCR, and NGS during clinical trials to support patient stratification, monitor drug efficacy, and ensure safety. qPCR and dPCR provide precise mutation detection and gene expression analysis to assess treatment responses in real-time, while NGS enables comprehensive tracking of therapeutic efficacy and the detection of potential adverse effects, optimizing patient outcomes and ensuring clinical success.
Molecular analyses in drug development
Molecular analysis across drug development
We accelerate time-to-market with rapid and reliable data, enabling informed stage-gate decisions and preparing submission-ready reports. We excel at identifying and monitoring nucleic acid biomarkers essential for understanding target engagement, efficacy, potency, and safety of cell, gene, and RNA therapies.
Discovery
Our services in the discovery phase focus on drug target identification and biomarker discovery. We utilize gene expression profiling and genomic analysis to uncover potential drug targets and identify novel biomarkers associated with disease mechanisms. Leveraging advanced technologies such as NGS, qPCR/dPCR, and proteomics, we discover genetic mutations, gene expression patterns, and early-stage biomarkers that can be validated in later phases of development.
Preclinical
In the preclinical phase, our molecular analysis services validate discovered biomarkers and further characterize genomic mutations identified during the discovery phase. We use qPCR, dPCR, and NGS to confirm biomarkers’ accuracy, reproducibility, and clinical relevance. Additionally, our genomic profiling ensures the integrity of cell and gene therapies, identifying potential mutations or safety risks in therapeutic models before progressing to clinical trials.
Clinical
We leverage qPCR, dPCR, and NGS during clinical trials to support patient stratification, monitor drug efficacy, and ensure safety. qPCR and dPCR provide precise mutation detection and gene expression analysis to assess treatment responses in real-time, while NGS enables comprehensive tracking of therapeutic efficacy and the detection of potential adverse effects, optimizing patient outcomes and ensuring clinical success.
Our expertise is based on over two decades of experience in the nucleic acid analysis field, and is supported by a state-of-the-art sample management operation, automated workflows, and a digital laboratory ecosystem (LIMS, ELN).
We take pride in delivering rapid, robust and reproducible results that are submission-ready.
This is achieved through:
- Use of the highest quality reagents, often internally designed and always tested through our validation process.
- Adherence to dedicated controls that are optimized for each project.
- Standardization and harmonization of all processes related to sample preparation, handling and analysis.
- Collaboration between Research, Service and Quality Assurance teams
Multi-Omics Integration
We are a leading provider of non-siloed, integrated multiomics analyses
We combine the design and interpretation of your genomics, transcriptomics, proteomics, microbiome and single-cell data into submission-ready reports.
We support study design and data interpretation, from pre-analytical imperatives to biostatistical analysis via dataset power calculations.
CUSTOMER-FOCUSED
Consistent, quality services
We focus on customer needs, no matter how challenging. Our project managers provide advice driven by our internal, leading-edge Research & Development Group.
We design and deliver custom solutions according to the needs of our partners. We develop tailor-made solutions with you and for you:
- Experiment design and sample handling
- Sample extraction, storage, and transportation
- Instrumentation selection and method development
- Assay, reagent, and control design
- Troubleshooting and optimization
- Technology transfer and training
- Data analysis and biostatistics
Accreditations & CERTIFICATIONS
